🇺🇸 FDA
Pipeline program

KYV-101 (Biological) - 0.33 ×10^8 cells

23-40657

Phase 1 mab active

Quick answer

KYV-101 (Biological) - 0.33 ×10^8 cells for Progressive Multiple Sclerosis is a Phase 1 program (mab) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Kyverna Therapeutics
Indication
Progressive Multiple Sclerosis
Phase
Phase 1
Modality
mab
Status
active

Clinical trials